To get in touch with XenTech, simply fill out the form below.
Subscribe to Supplier
XenTech brings new patient stratification insights to EORTC-NCI-AACR Symposium 2014
Evry, France: – Preclinical contract research organisation XenTech will present its latest tumor models as well as new scientific insights on use of PDX models to assist patient stratification when it attends the upcoming symposium on molecular target and cancer therapeutics.
XenTech’s founder and Chief Scientific Officer, Jean-Gabriel Judde, will lead the company’s team at the EORTC-NCI-AACR Symposium in Barcelona, opening on November 18th.
XenTech will contribute two posters on recent scientific advances in its use of patient-derived xenograft (PDX) tumor models to develop preclinical tools to evaluate the efficacy of new ADCs on human tumors.
The first poster, Nb 055, will present details of a panel of pediatric liver cancer patient-derived xenografts that can improve stratification of children with hepatoblastoma.
The second, Poster Nb 168, will show how combination of molecular and drug response data in patient-derived xenografts can also assist patient stratification.
XenTech will also be an exhibitor at the event. The CRO’s stand at Booth (A03) in Barcelona’s CCIB Center will host face-to-face meetings with current clients and partners, as well as potential new partners.
“Our booth should provide a perfect meeting point for our audience to discuss their projects directly with our team,” said XenTech’s Laboratory Head of R&D, said Dr. Stefano Cairo, who will also attend the symposium.
“The presence of our Scientific Director, Dr. Judde, at this event represents a great opportunity for our clients and partners to address specific scientific questions and to get deep scientific information,” Dr. Cairo added.
“We are also looking to exchange information to initiate and develop new scientific collaborations,” added Dr. Cairo, who has recently played a key role in important new research into liver cancer amongst children.
Oncology and biomarker expertise
Dr. Jean-GabrielJudde said XenTech had attended every EORTC-NCI-AACR symposium since 2010.
“The symposium’s focus on Molecular Targets and Cancer Therapeutics exactly describes the core fields of our expertise and our involvement in cancer research,” Dr. Judde noted.
“The high level of the conferences, posters and delegates provides us with a great forum to reach new partners and establish long-term collaborations with stakeholders in oncology research,” he added.
“They appreciate that we have one of the most characterized collections of Patient-Derived tumor Xenograft (PDX) models in the world and very deep knowledge of cancer models,” Dr. Judde declared.
XenTech is a highly innovative French-based biotech laboratory and CRO specializing in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX), which closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, and genomics and drug response.
XenTech is known worldwide for its renowned oncology translational platform and its unique panel of patient-derived breast cancer xenografts and its extremely experienced scientific team.
Since its foundation in April 2006, XenTech has assembled one of the world’s most impressive collections of PDX models that are extensively characterized by and associated with molecular data, including gene expression, copy number data, and manually curated mutations. Its preclinical platform is of considerable value to translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine.
XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.
About EORTC-NCI-AACR Symposium
The 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will take place in Barcelona, 18-21 November 2014.
Jointly hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2014 Symposium will discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology.
The event is expected to attract around 2,000 academics, scientists and pharmaceutical industry representatives from around the globe to the Centre de Convencions Internacional Barcelona (CCIB).
The conference will be combined with an industry exhibition featuring more than 30 research-based organizations and companies.
The event is administered by European Cancer Organization (ECCO), which says the symposium is unique in providing a scientific forum for developing drugs for the future.
The 2014 event aims to build on the success of the 2013 symposium in Boston, which was widely praised for the quality of its programme, inspirational contributions and exclusive insights.
More information at http://www.ecco-org.eu/Events/EORTC_NCI_AACR_2014